Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 732 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Genotyping Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Personalized Environment and Genes Study

NCT00341237
View directory record Official record
Conditions
Diabetes, Heart Disease, Asthma
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 8:38 PM EDT
Recruiting No phase listed Observational

Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions

NCT02077894
View directory record Official record
Conditions
Genetic Eye Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Day to 120 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 8:38 PM EDT
Not listed Phase 4 Interventional

Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol

NCT04049786
View directory record Official record
Conditions
Obesity, Bariatric Surgery, Roux-en Y Gastric Bypass
Interventions
Digestive biopsy, Carvedilol 25mg, Serial blood sampling for PK analysis, Metoprolol 100 mg for CYP2D6 phenotyping, Simvastatin 40mg, Midazolam 2 mg for CYP3A4 phenotyping, Genotyping
Procedure · Drug · Other
Lead sponsor
Natalia Valadares de Moraes
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 20, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT01314261
View directory record Official record
Conditions
Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
Interventions
ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV), Placebo for ABT-267
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 20, 2026, 8:38 PM EDT
Terminated Phase 3 Interventional

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

NCT06304883
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Experimental: ALZ-801
Drug
Lead sponsor
Alzheon Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Phoenix, Arizona • Sun City, Arizona • Costa Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 20, 2026, 8:38 PM EDT
Completed No phase listed Observational

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

NCT02345356
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Coagulopathies, Pulmonary Embolism
Interventions
Genotype-guided, Standard-of-Care
Genetic · Other
Lead sponsor
University of Puerto Rico
Other
Eligibility
21 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 20, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

NCT01958281
View directory record Official record
Conditions
HCV Infection
Interventions
SOF, RBV, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 20, 2026, 8:38 PM EDT
Completed No phase listed Observational

Heart and Skeletal Muscle Problems in Neuroacanthocytosis

NCT00007228
View directory record Official record
Conditions
Choreatic Disorder
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Hepatitis E Vaccine (HEV239)

NCT03827395
View directory record Official record
Conditions
Hepatitis E, Immunisation
Interventions
HEV 239, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 20, 2026, 8:38 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

NCT03117751
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Interventions
Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 20, 2026, 8:38 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

NCT00627926
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo
Biological · Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 20, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

NCT00663208
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Daclatasvir, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 20, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

NCT01909804
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Long Beach, California • Los Angeles, California • Pasadena, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 20, 2026, 8:38 PM EDT
Completed Phase 4 Interventional Results available

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

NCT00707863
View directory record Official record
Conditions
Major Depression
Interventions
Escitalopram
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 20, 2026, 8:38 PM EDT
Not listed Phase 2 Interventional

Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

NCT01872936
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Miravirsen, Telaprevir, Ribavirin
Drug
Lead sponsor
Santaris Pharma A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 20, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype

NCT00651638
View directory record Official record
Conditions
Healthy
Interventions
Treatment with ARQ 197
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 19, 2008 · Synced Oct 20, 2026, 8:38 PM EDT
Completed No phase listed Observational

Transition of Renal Patients Using AlloSure Into Community Kidney Care

NCT04601155
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AlloSure
Device
Lead sponsor
CareDx
Industry
Eligibility
12 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Fairfield, California • Fresno, California • Granada Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 20, 2026, 8:38 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

NCT07548632
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Artificial Tear Run-in, licaminlimab, Vehicle of licaminlimab
Other · Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
14
States / cities
Aliso Viejo, California • Garden Grove, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 20, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Green Tea and Reduction of Breast Cancer Risk

NCT00917735
View directory record Official record
Conditions
Breast Cancer
Interventions
Green tea extract supplement, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
1,075 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
5
States / cities
Edina, Minnesota • Maple Grove, Minnesota • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 20, 2026, 8:38 PM EDT
Completed Phase 2 Interventional

Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease

NCT00186810
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Busulfan, Cyclophosphamide, Horse ATG, Allogeneic stem cell transplant
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2009 · Synced Oct 20, 2026, 8:38 PM EDT
Terminated Phase 3 Interventional Results available

Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis

NCT02455167
View directory record Official record
Conditions
Hepatitis C
Interventions
Simeprivir (SMV), Sofosbuvir (SOF), Ribavirin (RBV)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 20, 2026, 8:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa

NCT00006298
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 20, 2026, 8:38 PM EDT
Completed Phase 2 Interventional

Ph IIA Study (SOC +/- NS5B)

NCT01193361
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-791325, Placebo, Peg-interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 20, 2026, 8:38 PM EDT
Active, not recruiting Not applicable Interventional

Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies

NCT04699786
View directory record Official record
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
Arm A , Arm B, Arm C, & Arm D
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 20, 2026, 8:38 PM EDT